These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 22315351)
1. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Urbanska K; Lanitis E; Poussin M; Lynn RC; Gavin BP; Kelderman S; Yu J; Scholler N; Powell DJ Cancer Res; 2012 Apr; 72(7):1844-52. PubMed ID: 22315351 [TBL] [Abstract][Full Text] [Related]
2. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting. Sutherland AR; Owens MN; Geyer CR Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850 [TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. Curran KJ; Pegram HJ; Brentjens RJ J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649 [TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860 [TBL] [Abstract][Full Text] [Related]
5. CAR T Cell Therapy for Solid Tumors. Newick K; O'Brien S; Moon E; Albelda SM Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544 [TBL] [Abstract][Full Text] [Related]
6. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. Yang QY; Yang JD; Wang YS Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818 [TBL] [Abstract][Full Text] [Related]
7. A new therapeutic potential for cancers: One CAR with 2 different engines! Sheikhi A; Jafarzadeh A Hum Vaccin Immunother; 2017 Aug; 13(8):1786-1788. PubMed ID: 28494200 [TBL] [Abstract][Full Text] [Related]
8. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Chandran SS; Klebanoff CA Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495 [TBL] [Abstract][Full Text] [Related]
9. Engineering switchable and programmable universal CARs for CAR T therapy. Liu D; Zhao J; Song Y J Hematol Oncol; 2019 Jul; 12(1):69. PubMed ID: 31272471 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137 [No Abstract] [Full Text] [Related]
11. Redirected T cells in cancer therapy. Sangiolo D Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608 [TBL] [Abstract][Full Text] [Related]
12. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521 [TBL] [Abstract][Full Text] [Related]
13. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661 [TBL] [Abstract][Full Text] [Related]
14. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Shirasu N; Kuroki M Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678 [TBL] [Abstract][Full Text] [Related]
15. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells. Hughes-Parry HE; Cross RS; Jenkins MR Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219 [TBL] [Abstract][Full Text] [Related]
16. Improving the efficacy and safety of engineered T cell therapy for cancer. Shi H; Liu L; Wang Z Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475 [TBL] [Abstract][Full Text] [Related]
17. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging. Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178 [TBL] [Abstract][Full Text] [Related]
18. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. Han C; Kwon BS Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727 [TBL] [Abstract][Full Text] [Related]
20. Masked Chimeric Antigen Receptor for Tumor-Specific Activation. Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]